Eric Hughes
Patrimonio netto: 4 M $ in data 31/05/2026
Patrimonio netto: 4 M $ in data 31/05/2026
Dr. Eric A. Hughes is an Independent Director at Monte Rosa Therapeutics, Inc. and a Chief Medical Officer, Executive VP-Global R&D at Teva Pharmaceutical Industries Ltd. He is on the Board of Directors at Monte Rosa Therapeutics, Inc. Dr. Hughes was previously employed as a SVP-Clinical Development & Translational Medicine by Vertex Pharmaceuticals, Inc. He received his graduate degree from Yale School of Medicine and a doctorate degree from Yale School of Medicine.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 20/03/2026 | 107.711 ( 0,01% ) | 4 M $ | 31/05/2026 | |
| 11/06/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Direttore Tecnico/Scientifico/R&S | 01/08/2022 |
| MONTE ROSA THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 13/12/2024 |
| Società | Posizione | Fine |
|---|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 4 |
|---|---|
Vertex Pharmaceuticals, Inc.
Vertex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops drugs for the treatment of cystic fibrosis | Health Technology |
Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. Pharmaceuticals: GenericHealth Technology Manufactures and markets generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients | Health Technology |
Yale School of Medicine
Yale School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops molecular glue degrader medicines for oncology, autoimmune and inflammatory diseases | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale